Affinity DataKi: 0.300nMAssay Description:Competitive inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells in presence of ATPMore data for this Ligand-Target Pair
Affinity DataKi: 7nMAssay Description:Competitive inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells in presence of ATPMore data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.100nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.200nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.300nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.600nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.700nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.800nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant mouse aurora kinase A expressed in insect Sf9 cells using biotin-GLRRASLG as substrate in presence of [gamma-33P]ATPMore data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.20nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.60nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 1.70nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.10nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.30nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.5nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 2.90nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair